C12Y 301/04035
3',5'-cyclic-gmp phosphodiesterase
Official title: 3',5'-Cyclic-GMP phosphodiesterase (3.1.4.35)
C12Y301/04035 (3',5'-cyclic-gmp phosphodiesterase) appears on 3 US grants and 12 published applications in this corpus.
Search patents in C12Y- Granted patents
- 3
- Published applications
- 12
- Assignees
- 12
- Inventors
- 36
- Latest grant
- 6 Jun 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 1 | 2 |
| 2022 | 1 | 2 |
| 2023 | 1 | 1 |
| 2024 | 0 | 0 |
| 2025 | 0 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- PDE5 compositions and methods for immunotherapy6 Jun 2023US 11,666,642 B2Obsidian Therapeutics, Inc.
- PDE5 compositions and methods for immunotherapy8 Feb 2022US 11,241,485 B2Obsidian Therapeutics, Inc.
- Recombinant adeno-associated virus particle purification comprising an affinity purification step1 Jun 2021US 11,021,689 B2Association Francaise Contre Les Myopathies
- Compound for treatment of erectile dysfunction30 Jul 2026US 2026/0216166 A1Initiator Pharma A/S
- Pde5 compositions and methods for immunotherapy9 Mar 2023US 2023/0074330 A1Obsidian Therapeutics, Inc.
- Pde5 derived regulatory constructs and methods of use in immunotherapy22 Dec 2022US 2022/0403001 A1Obsidian Therapeutics, Inc.
- Methods of Treating Epilepsy via Phosphodiesterase 4 (PDE4) Inhibition31 Mar 2022US 2022/0098257 A1Path Therapeutics, Inc.
- Recombinant adeno-associated virus particle purification comprising an affinity purification step21 Oct 2021US 2021/0324343 A1Association Francaise Contre Les Myopathies
Most cited
By later US patents
- PDE5 compositions and methods for immunotherapy9US 11,666,642 B2Obsidian Therapeutics, Inc. · 2023
- PDE5 compositions and methods for immunotherapy8US 11,241,485 B2Obsidian Therapeutics, Inc. · 2022
- Recombinant adeno-associated virus particle purification comprising an affinity purification step5US 11,021,689 B2Association Francaise Contre Les Myopathies · 2021